Celebrating 25 years Est 1999-2024
*Across 3 years $2276.64 only $1138.32
New clinical trial supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc.Avelumab (BAVENCIO®) to...
Putting the Patient First: Merck Serono to Present Data That Embodies the ESMO 2014 Theme of 'Precision Medicine in Cancer Care' PR...
Merck Serono Awards Grant for Growth Innovation (GGI) for the First Time PR Newswire DARMSTADT, Germany, September 19, 2014 DARMSTADT, Germany...
Merck Announces Detailed 26-Week Results from Phase IIIb Study with Kuvan in Children with PKU Below 4 Years of Age PR Newswire DARMSTADT...
Merck Serono Announces Groundbreaking of New Pharmaceutical Manufacturing Facility in China, its Second Largest Worldwide PR Newswire NANTONG...
Merck Serono Announces FDA Clearance for Auxogyn's Early Embryo Viability Assessment (Eeva®) System PR Newswire DARMSTADT, Germany, June 10, 2014...
EMD Serono to Release New Pipeline Data at ASCO 2014 from Early-Stage Investigational Compounds in Difficult-to-Treat Cancers PR...
Merck Serono's President & CEO Belén Garijo has Been Appointed to Board of Directors of L'Oréal PR Newswire DARMSTADT, Germany and PARIS...
European Commission Approves Update of Erbitux Metastatic Colorectal Cancer Labeling to Patients With RAS Wild-Type Tumors PR Newswire DARMSTADT...
Merck Enters Into License Agreement With the Spanish National Cancer Research Centre (CNIO) PR Newswire DARMSTADT, Germany, December 18, 2013...
Merck Serono Announces New Publication of Results of the Phase III START Trial Investigating Tecemotide in Non-Small Cell Lung Cancer in The...
Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.